Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Update

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a large increase in short interest in June. As of June 30th, there was short interest totaling 282,012 shares, an increase of 375.6% from the June 15th total of 59,293 shares. Based on an average daily trading volume, of 392,720 shares, the short-interest ratio is currently 0.7 days. Currently, 0.0% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, June 23rd. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Fresenius SE & Co. currently has an average rating of “Buy”.

Fresenius SE & Co. Price Performance

Shares of OTCMKTS FSNUY traded up $0.06 during mid-day trading on Friday, reaching $12.18. The company’s stock had a trading volume of 78,030 shares, compared to its average volume of 221,486. The stock has a 50-day moving average of $11.42 and a two-hundred day moving average of $13.02. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.98 and a current ratio of 1.27. The stock has a market capitalization of $27.44 billion, a P/E ratio of 16.24 and a beta of 0.63. Fresenius SE & Co. has a 1-year low of $10.33 and a 1-year high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.09% and a net margin of 6.55%.The business had revenue of $6.75 billion for the quarter, compared to analyst estimates of $6.79 billion. On average, equities research analysts anticipate that Fresenius SE & Co. will post 1.03 EPS for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.